PeptiDream (4587) Q3 2025 earnings summary

Executive summary

• Revenue for the nine months ended September 30, 2025, was ¥12.86 billion, down ¥28.75 billion year-over-year, with a net loss attributable to owners of parent of ¥3.22 billion compared to a profit of ¥17.62 billion in the prior year.

• The Drug Discovery and Development segment saw a sharp revenue decline and segment loss, while the Radiopharmaceutical segment grew revenue and profit.

• Cash and cash equivalents decreased by ¥17.59 billion to ¥30.53 billion, mainly due to operating losses and tax payments.

Financial highlights

• Core operating loss was ¥3.98 billion, compared to a core operating profit of ¥24.66 billion year-over-year.

• Operating loss was ¥4.06 billion, versus an operating profit of ¥24.52 billion in the prior year.

• Gross profit fell to ¥4.84 billion from ¥32.54 billion year-over-year.

• Basic and diluted loss per share was ¥(24.88), compared to earnings per share of ¥135.95 in the prior year.

• Total assets decreased to ¥77.57 billion from ¥92.77 billion at year-end 2024.

Outlook and guidance

• Full-year 2025 revenue is forecast at ¥49.0 billion (+5.0% year-over-year), with profit attributable to owners of parent projected at ¥15.1 billion (+0.6%).

• No revisions to the previously announced financial forecast.